• NEWCELX. (NCEL)
  • $-- --- (--%)
  • NASDAQ Capital Market
Layer 0

Investors

Corporate Overview

NewcelX Ltd. (Nasdaq: NCEL) is advancing NCEL-101, a stem cell-derived islet replacement therapy designed to restore functional insulin production, toward a potential functional cure for type 1 diabetes.

Contact us for investor relations at: [email protected]

Press Releases